NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00206180|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : March 26, 2009
|Condition or disease||Intervention/treatment||Phase|
|Erosive Esophagitis Reflux Esophagitis Gastroesophageal Reflux Disease||Drug: esomeprazole magnesium (oral medication)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily|
|Study Start Date :||June 2004|
|Study Completion Date :||August 2005|
- To determine the relationship between 24-hour intragastric pH at Day 5 and healing status of moderate to severe erosive esophagitis, after 4 weeks of treatment with 2 doses of esomeprazole magnesium.
- Secondary outcomes and the relationship to pH will also be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00206180
Show 39 Study Locations
|Study Director:||Nexium Medical Science Director, MD||AstraZeneca|